O	0	9	Selective	Selective	JJ	B-NP
O	10	20	inhibition	inhibition	NN	I-NP
O	21	23	of	of	IN	B-PP
O	24	31	nuclear	nuclear	JJ	B-NP
O	32	38	factor	factor	NN	I-NP
O	38	39	-	-	HYPH	O
O	39	45	kappaB	kappaB	NN	B-NP
O	46	48	by	by	IN	B-PP
O	49	56	nuclear	nuclear	JJ	B-NP
O	57	63	factor	factor	NN	I-NP
O	63	64	-	-	HYPH	B-NP
O	64	70	kappaB	kappaB	NN	I-NP
O	71	80	essential	essential	JJ	I-NP
O	81	90	modulator	modulator	NN	I-NP
O	90	91	-	-	HYPH	O
O	91	98	binding	bind	VBG	B-VP
O	99	105	domain	domain	NN	B-NP
O	106	113	peptide	peptide	NN	I-NP
O	114	124	suppresses	suppress	VBZ	B-VP
O	125	128	the	the	DT	B-NP
O	129	139	metastasis	metastasis	NN	I-NP
O	140	142	of	of	IN	B-PP
O	143	149	highly	highly	RB	B-NP
B-Cancer	150	160	metastatic	metastatic	JJ	I-NP
I-Cancer	161	165	oral	oral	JJ	I-NP
I-Cancer	166	174	squamous	squamous	JJ	I-NP
I-Cancer	175	179	cell	cell	NN	I-NP
I-Cancer	180	189	carcinoma	carcinoma	NN	I-NP
O	189	190	.	.	.	O

O	192	199	Nuclear	Nuclear	JJ	B-NP
O	200	206	factor	factor	NN	I-NP
O	206	207	-	-	HYPH	O
O	207	213	kappaB	kappaB	NN	B-NP
O	214	215	(	(	(	O
O	215	217	NF	NF	NN	B-NP
O	217	218	-	-	HYPH	B-NP
O	218	224	kappaB	kappaB	NN	I-NP
O	224	225	)	)	)	O
O	226	236	activation	activation	NN	B-NP
O	237	248	contributes	contribute	VBZ	B-VP
O	249	251	to	to	TO	B-PP
O	252	255	the	the	DT	B-NP
O	256	267	development	development	NN	I-NP
O	268	270	of	of	IN	B-PP
O	271	281	metastasis	metastasis	NN	B-NP
O	281	282	,	,	,	O
O	283	287	thus	thus	RB	B-ADVP
O	288	295	leading	lead	VBG	B-VP
O	296	298	to	to	TO	B-PP
O	299	300	a	a	DT	B-NP
O	301	305	poor	poor	JJ	I-NP
O	306	315	prognosis	prognosis	NN	I-NP
O	316	318	in	in	IN	B-PP
O	319	323	many	many	JJ	B-NP
B-Cancer	324	331	cancers	cancer	NNS	I-NP
O	331	332	,	,	,	O
O	333	342	including	include	VBG	B-PP
B-Cancer	343	347	OSCC	OSCC	NN	B-NP
O	347	348	.	.	.	O

O	349	356	However	However	RB	B-ADVP
O	356	357	,	,	,	O
O	358	364	little	little	JJ	B-NP
O	365	367	in	in	FW	I-NP
O	368	372	vivo	vivo	FW	I-NP
O	373	385	experimental	experimental	JJ	I-NP
O	386	390	data	datum	NNS	I-NP
O	391	394	are	be	VBP	B-VP
O	395	404	available	available	JJ	B-ADJP
O	405	410	about	about	IN	B-PP
O	411	414	the	the	DT	B-NP
O	415	422	effects	effect	NNS	I-NP
O	423	425	of	of	IN	B-PP
O	426	428	NF	NF	NN	B-NP
O	428	429	-	-	HYPH	B-NP
O	429	435	kappaB	kappaB	NN	I-NP
O	436	446	inhibition	inhibition	NN	I-NP
O	447	449	on	on	IN	B-PP
B-Cancer	450	454	OSCC	OSCC	NN	B-NP
O	455	465	metastasis	metastasis	NN	I-NP
O	465	466	.	.	.	O

B-Cell	467	471	OSCC	OSCC	NN	B-NP
I-Cell	472	480	sublines	subline	NNS	I-NP
O	481	485	were	be	VBD	B-VP
O	486	497	established	establish	VBN	I-VP
O	498	502	from	from	IN	B-PP
O	503	504	a	a	DT	B-NP
O	505	508	GFP	GFP	NN	I-NP
O	508	509	-	-	HYPH	O
O	509	519	expressing	express	VBG	B-VP
B-Cell	520	528	parental	parental	JJ	B-NP
I-Cell	529	533	cell	cell	NN	I-NP
I-Cell	534	538	line	line	NN	I-NP
O	538	539	,	,	,	O
B-Cell	540	544	GSAS	GSAS	NN	B-NP
O	544	545	,	,	,	O
O	546	549	and	and	CC	O
O	550	560	designated	designate	VBN	B-NP
B-Cell	561	565	GSAS	GSAS	NN	I-NP
I-Cell	565	566	/	/	SYM	I-NP
I-Cell	566	568	N3	N3	NN	I-NP
O	569	572	and	and	CC	I-NP
B-Cell	573	575	N5	N5	NN	I-NP
O	576	585	according	accord	VBG	B-PP
O	586	588	to	to	TO	B-PP
O	589	592	the	the	DT	B-NP
O	593	595	in	in	FW	I-NP
O	596	600	vivo	vivo	FW	I-NP
O	601	608	passage	passage	NN	I-NP
O	609	615	number	number	NN	I-NP
O	616	621	after	after	IN	B-PP
B-Multi-tissue_structure	622	630	cervical	cervical	JJ	B-NP
I-Multi-tissue_structure	631	636	lymph	lymph	NN	I-NP
I-Multi-tissue_structure	637	641	node	node	NN	I-NP
O	642	652	metastasis	metastasis	NN	I-NP
O	653	655	by	by	IN	B-PP
O	656	657	a	a	DT	B-NP
O	658	664	serial	serial	JJ	I-NP
O	665	675	orthotopic	orthotopic	JJ	I-NP
O	676	691	transplantation	transplantation	NN	I-NP
O	692	697	model	model	NN	I-NP
O	697	698	.	.	.	O

O	699	701	In	In	FW	B-NP
O	702	707	vitro	vitro	FW	I-NP
O	708	717	migration	migration	NN	I-NP
O	718	721	and	and	CC	I-NP
O	722	730	invasion	invasion	NN	I-NP
O	731	735	were	be	VBD	B-VP
O	736	744	assessed	assess	VBN	I-VP
O	745	747	in	in	IN	B-PP
O	748	753	these	these	DT	B-NP
B-Cell	754	759	cells	cell	NNS	I-NP
O	759	760	,	,	,	O
O	761	764	and	and	CC	O
O	765	768	the	the	DT	B-NP
O	769	771	NF	NF	NN	I-NP
O	771	772	-	-	HYPH	B-NP
O	772	778	kappaB	kappaB	NN	I-NP
O	779	789	activities	activity	NNS	I-NP
O	790	793	and	and	CC	O
O	794	804	expression	expression	NN	B-NP
O	805	807	of	of	IN	B-PP
O	808	810	NF	NF	NN	B-NP
O	810	811	-	-	HYPH	B-NP
O	811	817	kappaB	kappaB	NN	I-NP
O	817	818	-	-	HYPH	O
O	818	827	regulated	regulate	VBN	B-NP
O	828	838	metastasis	metastasis	NN	I-NP
O	838	839	-	-	HYPH	O
O	839	846	related	relate	VBN	B-NP
O	847	856	molecules	molecule	NNS	I-NP
O	857	861	were	be	VBD	B-VP
O	862	866	also	also	RB	I-VP
O	867	875	examined	examine	VBN	I-VP
O	875	876	.	.	.	O

O	877	879	In	In	IN	B-PP
O	880	882	in	in	FW	B-NP
O	883	887	vivo	vivo	FW	I-NP
O	888	899	experiments	experiment	NNS	I-NP
O	899	900	,	,	,	O
O	901	904	the	the	DT	B-NP
O	905	915	metastasis	metastasis	NN	I-NP
O	916	919	and	and	CC	I-NP
O	920	928	survival	survival	NN	I-NP
O	929	931	of	of	IN	B-PP
B-Cancer	932	937	tumor	tumor	NN	B-NP
O	937	938	-	-	HYPH	B-NP
O	938	947	engrafted	engraft	VBN	I-NP
O	948	952	mice	mouse	NNS	I-NP
O	953	957	were	be	VBD	B-VP
O	958	967	monitored	monitor	VBN	I-VP
O	967	968	.	.	.	O

O	969	980	Furthermore	Furthermore	RB	B-ADVP
O	980	981	,	,	,	O
O	982	985	the	the	DT	B-NP
O	986	993	effects	effect	NNS	I-NP
O	994	996	of	of	IN	B-PP
O	997	998	a	a	DT	B-NP
O	999	1008	selective	selective	JJ	I-NP
O	1009	1011	NF	NF	NN	I-NP
O	1011	1012	-	-	HYPH	B-NP
O	1012	1018	kappaB	kappaB	NN	I-NP
O	1019	1028	inhibitor	inhibitor	NN	I-NP
O	1028	1029	,	,	,	O
O	1030	1034	NEMO	NEMO	NN	B-NP
O	1034	1035	-	-	HYPH	O
O	1035	1042	binding	bind	VBG	B-VP
O	1043	1049	domain	domain	NN	B-NP
O	1050	1051	(	(	(	O
O	1051	1054	NBD	NBD	NN	B-NP
O	1054	1055	)	)	)	O
O	1056	1063	peptide	peptide	NN	B-NP
O	1063	1064	,	,	,	O
O	1065	1067	on	on	IN	B-PP
O	1068	1078	metastasis	metastasis	NN	B-NP
O	1079	1081	in	in	IN	B-PP
B-Cell	1082	1086	GSAS	GSAS	NN	B-NP
I-Cell	1086	1087	/	/	SYM	B-NP
I-Cell	1087	1089	N5	N5	NN	I-NP
O	1089	1090	-	-	HYPH	B-NP
O	1090	1099	engrafted	engraft	VBN	I-NP
O	1100	1104	mice	mouse	NNS	I-NP
O	1105	1109	were	be	VBD	B-VP
O	1110	1118	assessed	assess	VBN	I-VP
O	1118	1119	,	,	,	O
O	1120	1123	and	and	CC	O
O	1124	1133	engrafted	engraft	VBN	B-NP
B-Cancer	1134	1140	tongue	tongue	NN	I-NP
I-Cancer	1141	1147	tumors	tumor	NNS	I-NP
O	1148	1152	were	be	VBD	B-VP
O	1153	1174	immunohistochemically	immunohistochemically	RB	I-VP
O	1175	1183	examined	examine	VBN	I-VP
O	1183	1184	.	.	.	O

O	1185	1191	Highly	Highly	RB	B-NP
B-Cell	1192	1202	metastatic	metastatic	JJ	I-NP
I-Cell	1203	1207	GSAS	GSAS	NN	I-NP
I-Cell	1207	1208	/	/	SYM	B-NP
I-Cell	1208	1210	N3	N3	NN	I-NP
O	1211	1214	and	and	CC	I-NP
B-Cell	1215	1217	N5	N5	NN	I-NP
I-Cell	1218	1223	cells	cell	NNS	I-NP
O	1224	1230	showed	show	VBD	B-VP
O	1231	1233	an	an	DT	B-NP
O	1234	1242	enhanced	enhance	VBN	I-NP
O	1243	1245	NF	NF	NN	I-NP
O	1245	1246	-	-	HYPH	I-NP
O	1246	1252	kappaB	kappaB	NN	I-NP
O	1253	1261	activity	activity	NN	I-NP
O	1261	1262	,	,	,	O
O	1263	1267	thus	thus	RB	B-ADVP
O	1268	1280	contributing	contribute	VBG	B-VP
O	1281	1283	to	to	TO	B-PP
O	1284	1293	increased	increase	VBN	B-NP
O	1294	1303	migration	migration	NN	I-NP
O	1303	1304	,	,	,	O
O	1305	1313	invasion	invasion	NN	B-NP
O	1313	1314	,	,	,	O
O	1315	1318	and	and	CC	O
O	1319	1320	a	a	DT	B-NP
O	1321	1325	poor	poor	JJ	I-NP
O	1326	1335	prognosis	prognosis	NN	I-NP
O	1336	1344	compared	compare	VBN	B-PP
O	1345	1349	with	with	IN	B-PP
O	1350	1353	the	the	DT	B-NP
O	1354	1360	parent	parent	NN	I-NP
B-Cell	1361	1366	cells	cell	NNS	I-NP
O	1366	1367	.	.	.	O

O	1368	1379	Furthermore	Furthermore	RB	B-ADVP
O	1379	1380	,	,	,	O
O	1381	1384	the	the	DT	B-NP
O	1385	1395	expression	expression	NN	I-NP
O	1396	1402	levels	level	NNS	I-NP
O	1403	1405	of	of	IN	B-PP
O	1406	1408	NF	NF	NN	B-NP
O	1408	1409	-	-	HYPH	B-NP
O	1409	1415	kappaB	kappaB	NN	I-NP
O	1415	1416	-	-	HYPH	O
O	1416	1425	regulated	regulate	VBN	B-NP
O	1426	1436	metastasis	metastasis	NN	I-NP
O	1436	1437	-	-	HYPH	O
O	1437	1444	related	relate	VBN	B-NP
O	1445	1454	molecules	molecule	NNS	I-NP
O	1454	1455	,	,	,	O
O	1456	1460	such	such	JJ	B-PP
O	1461	1463	as	as	IN	I-PP
O	1464	1475	fibronectin	fibronectin	NN	B-NP
O	1475	1476	,	,	,	O
O	1477	1482	beta1	beta1	NN	B-NP
O	1483	1491	integrin	integrin	NN	I-NP
O	1491	1492	,	,	,	O
O	1493	1496	MMP	MMP	NN	B-NP
O	1496	1497	-	-	HYPH	B-NP
O	1497	1498	1	1	CD	I-NP
O	1498	1499	,	,	,	O
O	1500	1501	-	-	HYPH	B-NP
O	1501	1502	2	2	CD	I-NP
O	1502	1503	,	,	,	O
O	1504	1505	-	-	HYPH	B-NP
O	1505	1506	9	9	CD	I-NP
O	1506	1507	,	,	,	O
O	1508	1511	and	and	CC	O
O	1512	1513	-	-	HYPH	B-NP
O	1513	1515	14	14	CD	I-NP
O	1515	1516	,	,	,	O
O	1517	1520	and	and	CC	O
O	1521	1525	VEGF	VEGF	NN	B-NP
O	1525	1526	-	-	HYPH	I-NP
O	1526	1527	C	C	NN	I-NP
O	1527	1528	,	,	,	O
O	1529	1533	were	be	VBD	B-VP
O	1534	1545	upregulated	upregulate	VBN	I-VP
O	1546	1548	in	in	IN	B-PP
O	1549	1552	the	the	DT	B-NP
O	1553	1559	highly	highly	RB	I-NP
B-Cell	1560	1570	metastatic	metastatic	JJ	I-NP
I-Cell	1571	1576	cells	cell	NNS	I-NP
O	1576	1577	.	.	.	O

O	1578	1581	The	The	DT	B-NP
O	1582	1585	NBD	NBD	NN	I-NP
O	1586	1593	peptide	peptide	NN	I-NP
O	1594	1604	suppressed	suppress	VBD	B-VP
O	1605	1615	metastasis	metastasis	NN	B-NP
O	1616	1619	and	and	CC	I-NP
B-Cancer	1620	1626	tongue	tongue	NN	I-NP
I-Cancer	1627	1632	tumor	tumor	NN	I-NP
O	1633	1639	growth	growth	NN	I-NP
O	1640	1642	in	in	IN	B-PP
B-Cell	1643	1647	GSAS	GSAS	NN	B-NP
I-Cell	1647	1648	/	/	SYM	B-NP
I-Cell	1648	1650	N5	N5	NN	I-NP
O	1650	1651	-	-	HYPH	B-NP
O	1651	1661	inoculated	inoculate	VBN	I-NP
O	1662	1666	mice	mouse	NNS	I-NP
O	1666	1667	,	,	,	O
O	1668	1671	and	and	CC	O
O	1672	1675	was	be	VBD	B-VP
O	1676	1687	accompanied	accompany	VBN	I-VP
O	1688	1690	by	by	IN	B-PP
O	1691	1694	the	the	DT	B-NP
O	1695	1709	downregulation	downregulation	NN	I-NP
O	1710	1712	of	of	IN	B-PP
O	1713	1716	the	the	DT	B-NP
O	1717	1719	NF	NF	NN	I-NP
O	1719	1720	-	-	HYPH	B-NP
O	1720	1726	kappaB	kappaB	NN	I-NP
O	1726	1727	-	-	HYPH	O
O	1727	1736	regulated	regulate	VBN	B-NP
O	1737	1747	metastasis	metastasis	NN	I-NP
O	1747	1748	-	-	HYPH	O
O	1748	1755	related	relate	VBN	B-NP
O	1756	1765	molecules	molecule	NNS	I-NP
O	1766	1768	in	in	IN	B-PP
O	1769	1778	engrafted	engraft	VBN	B-NP
B-Cancer	1779	1785	tongue	tongue	NN	I-NP
I-Cancer	1786	1792	tumors	tumor	NNS	I-NP
O	1792	1793	.	.	.	O

O	1794	1797	Our	Our	PRP$	B-NP
O	1798	1805	results	result	NNS	I-NP
O	1806	1813	suggest	suggest	VBP	B-VP
O	1814	1818	that	that	IN	B-SBAR
O	1819	1822	the	the	DT	B-NP
O	1823	1832	selective	selective	JJ	I-NP
O	1833	1843	inhibition	inhibition	NN	I-NP
O	1844	1846	of	of	IN	B-PP
O	1847	1849	NF	NF	NN	B-NP
O	1849	1850	-	-	HYPH	B-NP
O	1850	1856	kappaB	kappaB	NN	I-NP
O	1857	1867	activation	activation	NN	I-NP
O	1868	1870	by	by	IN	B-PP
O	1871	1874	NBD	NBD	NN	B-NP
O	1875	1882	peptide	peptide	NN	I-NP
O	1883	1886	may	may	MD	B-VP
O	1887	1894	provide	provide	VB	I-VP
O	1895	1897	an	an	DT	B-NP
O	1898	1907	effective	effective	JJ	I-NP
O	1908	1916	approach	approach	NN	I-NP
O	1917	1920	for	for	IN	B-PP
O	1921	1924	the	the	DT	B-NP
O	1925	1934	treatment	treatment	NN	I-NP
O	1935	1937	of	of	IN	B-PP
O	1938	1944	highly	highly	RB	B-NP
B-Cancer	1945	1955	metastatic	metastatic	JJ	I-NP
I-Cancer	1956	1960	OSCC	OSCC	NN	I-NP
O	1960	1961	.	.	.	O

